Pfizer Inc. (PFE) and Astellas Announce Phase 3 ARCHES Trial Shows XTANDI Significantly Improved Radiographic PFS in Men with Metastatic Hormone-Sensitive Prostate Cancer
Tweet Send to a Friend
Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. announced today results from the Phase 3 ARCHES trial in men with ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
